Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

31 May 2012 07:00

RNS Number : 4649E
Biome Technologies PLC
31 May 2012
 



Biome Technologies plc ("Biome", "the Company" or "the Group")

Trading Update

 

In the trading statement released by Biome on 25 April, it was stated that revenues were slower to achieve than expected in the first quarter, particularly in the Bioplastics Division. Unfortunately, sales within this division have been markedly below our expectation during April and May. The Board now believes that this will have a significant adverse impact on the Group results for the full year; this will be particularly felt in the first half. The RF Division is trading in line with the Board's expectations and its order pipeline remains strong.

 

Customers of the Group's Bioplastics Division are reporting subdued demand for their own bioplastic end products, particularly in the markets of southern Europe. During 2011, the Italian market for bioplastics became one of the largest in Europe following the implementation of regulations (first introduced in early 2011 and reaffirmed in early 2012) mandating the use of biodegradable products for shopping bags. However, in the early part of May this year Biome became aware that the financial penalty for non-compliance with these regulations would now be deferred until the end of 2013. This has resulted in the recent and significant change in the adoption rate in the Italian market and a broader disruption to the supply and demand balance of bioplastics in Europe. In the current, year the Board expects its joint venture company, Biotec, to be the most adversely affected part of the Group.

 

The impact of these changes to the dynamics of the bioplastics' market will result in it taking longer than previously anticipated for the Group to reach profitability. The Group's cash balance as at the end of April was £1.4m. However, this would have reduced significantly as the year progressed unless action is taken to reduce costs. As a result, the Board is taking steps to reduce cash costs by approximately £600k per year. This will better preserve Biome's ability to reach profitability and protect its business model.

 

Whilst the above developments, which affect the fast development of Biome's bio-plastics market, are disappointing, the Board believes firmly that they constitute a pause in a fast-developing market rather than an indication of anything more fundamental.

 

Biome continues to progress successfully with new products and technologies to improve its future prospects and develop new markets. The RF Division is performing well and remains a cash generator for the group as a whole. The Durapipe project remains on track and is successfully passing agreed milestones with our partner. The new technology for heat and cold resistant bio-plastic materials continues to gain positive reaction from product tests with prospective customers. The Board expects these new developments to make contributions to turnover in 2013.

 

-Ends-

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

Daniel Stewart & Company plc

David Hart

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBKKDPABKDBPN
Date   Source Headline
21st Mar 20257:00 amRNSCancellation- Biome Technologies PLC
13th Mar 202512:22 pmRNSResult of GM & update on Cancellation
21st Feb 20257:00 amRNSProposed Cancellation & Notice of GM
18th Dec 20247:00 amRNSSecured Funding Facility
4th Dec 20247:00 amRNSTrading Update and Board Change
13th Nov 20247:00 amRNSTrading Update
25th Oct 20247:00 amRNSAppointment of Non-Executive Director
30th Sep 20245:00 pmRNSTotal Voting Rights
30th Sep 202411:08 amRNSContract win for Stanelco RF Division
20th Sep 20247:00 amRNSInterim Results
13th Sep 202410:58 amRNSHolding(s) in Company
12th Sep 202411:43 amRNSHolding(s) in Company
11th Sep 20243:01 pmRNSHolding(s) in Company
10th Sep 20247:00 amRNSHolding(s) in Company
9th Sep 20244:51 pmRNSHolding(s) in Company
4th Sep 20242:39 pmRNSResult of General Meeting and TVR
30th Aug 20245:00 pmRNSTotal Voting Rights
23rd Aug 20242:42 pmRNSHolding(s) in Company
22nd Aug 202411:00 amRNSHolding(s) in Company
22nd Aug 20247:00 amRNSResult of Retail Offer, Director dealing and TVR
21st Aug 20244:12 pmRNSHolding(s) in Company
21st Aug 20241:41 pmRNSHolding(s) in Company
16th Aug 20247:05 amRNSRetail offer to raise up to £80,000
16th Aug 20247:01 amRNSProposed Fundraise and other matters
16th Aug 20247:00 amRNSTrading update
10th Jul 20247:00 amRNSDirectorate Change
8th Jul 20247:00 amRNSTrading update
12th Jun 20247:00 amRNSGrant of Options
29th May 202410:57 amRNSResult of AGM, Interim CFO and Directorate Change
22nd May 20242:27 pmRNSContract win for Stanelco RF Division
15th May 20247:00 amRNSNotice of AGM and 2023 Annual Report
29th Apr 20247:01 amRNSTrading Update
29th Apr 20247:00 amRNSFinal Results 2023
15th Mar 20247:00 amRNSContract win for Stanelco RF Division
11th Mar 20241:59 pmRNSIssue of Convertible Loan Notes, PDMR Notification
15th Feb 20242:54 pmRNSContract win for RF Division
6th Feb 20247:00 amRNSTrading Update
13th Nov 20237:00 amRNSTrading Update
10th Oct 20234:32 pmRNSGrant of Options
27th Sep 20237:00 amRNSInterim Results
26th Jul 20237:00 amRNSTrading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20237:00 amRNSContract win for Stanelco RF Division
31st May 20237:00 amRNSIssue of Equity, Director/PDMR Shareholding & TVR
25th May 20232:57 pmRNSAppointment of Non-Executive Director
25th May 202312:45 pmRNSResult of AGM
2nd May 20231:05 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSNotice of AGM and 2022 Annual Report
26th Apr 20237:01 amRNSTrading Update
26th Apr 20237:00 amRNSFinal Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.